Xizang Haisco Pharmaceutical Group Co Ltd

AirNexis Therapeutics announced that AN01, a dual PDE3/4 inhibitor dry powder inhaler, met its primary endpoint in a Phase 2b COPD study conducted in China by its partner Haisco Pharmaceutical Group. The study, HSK39004-T1-202, randomized 195 patients on background single or dual bronchodilator therapy to receive AN01 0.75 mg, 1.5 mg, or placebo for four weeks. Both doses significantly improved lung function versus placebo, with treatment differences of 116 mL and 127 mL in FEV₁ AUC₀₋₁₂h at Week 4. AN01 was well tolerated, with no treatment-related adverse events in the 0.75 mg dose group, which is the dose being investigated in the Phase 3 program. AirNexis has completed its Phase 1 multiple ascending dose study in Australia and is preparing to initiate its Phase 2 program in 2027.

Haisco Pharmaceutical released its 2026 interim report. Total operating revenue was 3.096 billion yuan, net profit attributable to the parent company was 851 million yuan, and net operating cash inflow was 761 million yuan. The company's latest asset-liability ratio was 38.89%, up 2.11 percentage points from the previous quarter; gross margin was 80.24%, down 1.15 percentage points from the previous quarter; ROE was 17.68%. Diluted earnings per share was 0.76 yuan, total asset turnover was 0.42 times, and inventory turnover was 1.86 times, down 1.82% year on year. The number of shareholders was 24,500, and the top ten shareholders held 82.66% of total share capital.

The investors behind Metsera have founded a new biotech, Sentivera, which has licensed a preclinical immunology asset from China's Haisco Pharmaceutical. Population Health Partners and ARCH Venture Partners, who previously backed Metsera, are behind the new venture. Sentivera will pay $76 million upfront for global rights to the drug, excluding Greater China, with milestone payments potentially pushing the total deal value above $1.5 billion. Haisco, which received approval from China's National Medical Products Administration to begin clinical trials this month, will also earn royalties. The NewCo structure, which gives investors equity in the new company, is part of a growing trend in China-US pharma deals. The founders hope Sentivera will replicate the success of Metsera, which Pfizer acquired for $10 billion after a bidding war with Novo Nordisk.

On the evening of August 26, several A-share companies disclosed hefty dividend plans. Energy storage leader Deye plans to distribute 16 yuan in cash per 10 shares, totaling 2.037 billion yuan, representing 74.97% of net profit attributable to shareholders for the period. In the first half, the company achieved revenue of 10.641 billion yuan, up 92.23% year on year, with net profit attributable to shareholders of 2.717 billion yuan, up 78.53%. MicroPort Endovascular MedTech plans to distribute 13 yuan per 10 shares, totaling 157 million yuan, or 48.73% of first-half net profit attributable to shareholders. Giant Network plans to distribute 8 yuan per 10 shares, totaling 1.515 billion yuan, or 70.65% of net profit, and also released a shareholder dividend return plan for the next three years. NARI Technology plans to distribute 1.53 yuan per 10 shares, totaling 1.222 billion yuan, with first-half dividends and buybacks combined at 1.261 billion yuan, or 41.03% of net profit attributable to shareholders for the same period. In addition, China CITIC Bank plans to distribute 2.03 yuan per 10 shares, totaling 11.296 billion yuan; New China Life Insurance plans to distribute 7.3 yuan per 10 shares, totaling 2.277 billion yuan; Anhui Conch Cement plans to distribute 1.3 yuan per 10 shares, totaling 680 million yuan; Sinotruk plans to distribute 5.41 yuan per 10 shares, totaling 632 million yuan; Haisco Pharmaceutical plans to distribute 5.26 yuan per 10 shares, totaling 600 million yuan.

Haisco Pharmaceutical Group Co., Ltd. has entered into an exclusive license agreement with Sentivera Therapeutics, Inc. of the United States, granting it exclusive rights to develop, manufacture, and commercialize a preclinical autoimmune asset worldwide, excluding mainland China, Hong Kong, Macau, and Taiwan. Sentivera will pay an upfront fee of approximately 75.89 million US dollars, comprising 40 million US dollars in cash and approximately 35.89 million US dollars equivalent in Sentivera equity representing a 17.5 percent stake, as well as up to 1.46 billion US dollars in milestone payments, tiered royalties of up to 10 percent on net sales, and a share of sublicensing income. The asset is an oral small molecule formulation independently developed by Haisco, intended for the treatment of inflammatory diseases, and has received approval for clinical trials in China. Wang Junmin, the company's actual controller, invested 5 million US dollars in Sentivera for 1,666,667 shares, representing approximately 2.44 percent, constituting a related-party transaction. The matter has been approved by the board of directors and remains subject to shareholder approval.

Haisco Pharmaceutical Group announced that its self-developed Class 1 new chemical drug HSK60002 tablets have received clinical trial approval from the National Medical Products Administration. The drug is an oral small-molecule formulation intended for the treatment of inflammatory diseases. Preclinical study data show that HSK60002 tablets exhibit significant pharmacodynamic activity in relevant animal models, with a clear mechanism of action and promising development prospects. The company also cautioned that innovative drug development involves long cycles, high risks, and is susceptible to uncertainties.

Haisco Pharmaceutical Group announced it plans to use its own funds to provide a loan of up to 261 million yuan to its controlling subsidiary, Shanghai Haisco Geneo Biotechnology, for research and development investment and working capital turnover. The loan carries an annual interest rate of 3.05 percent and a term of five years. Haisco Geneo was established in March 2026, with the company holding an 86.69 percent stake, focusing on cutting-edge areas such as ADC and In Vivo CART. Minority shareholder Helix will provide financial assistance of up to 30 million yuan on the same terms in proportion to its capital contribution. As of the announcement date, the company's total outstanding financial assistance balance is 261 million yuan, accounting for 6.09 percent of net assets, with no overdue unrecovered amounts.

Haisco's self-developed oral small-molecule pain drug HSK51155 tablets have received clinical trial approval from the National Medical Products Administration. The drug is intended for the treatment of migraines and is expected to control pain while reducing adverse reactions and avoiding the risk of addiction. Previously, in April 2026, Haisco entered into a cooperation agreement with AbbVie Group Holdings Ltd., granting AbbVie exclusive rights to develop, manufacture, and commercialize the drug globally outside of mainland China, Hong Kong, and Macau, with a potential total transaction value exceeding 700 million US dollars. In the first quarter of 2026, Haisco achieved revenue of 1.564 billion yuan and net profit attributable to the parent company of 555 million yuan.

As of the close on July 23, 99 A-share biomedical companies have released their 2026 half-year earnings forecasts, with 60 projecting growth in net profit attributable to the parent and 39 forecasting a decline. Fushine Pharma expects net profit attributable to the parent to rise by 2,487 percent to 3,204 percent, Joinn Laboratories anticipates an increase of 884.9 percent to 1,377.4 percent, and Medicilon, Haisco Pharmaceutical, and ST Wanbang also see maximum growth exceeding 500 percent. The chemical pharmaceutical sector is broadly positive, with 25 of the 36 companies that issued forecasts expecting growth. The biologics segment is underperforming, with only 2 of the 9 companies that issued forecasts projecting an increase. Out-licensing of innovative drugs overseas is active, with total out-licensing deal value in the first half reaching approximately 110 billion US dollars. Haisco Pharmaceutical achieved significant performance growth through multiple out-licensing deals. The price of laboratory monkeys continues to rise, with the unit price of cynomolgus monkeys climbing to 178,000 yuan, driving substantial profit forecast increases for CRO companies such as Joinn Laboratories and Medicilon.

On July 8, several A-share companies disclosed their earnings forecasts, with many expecting their first-half net profit attributable to the parent company to multiply. SDG Information expects net profit attributable to the parent company to be between 55 million and 71 million yuan, a year-on-year increase of 881.42% to 1,166.93%, mainly due to the completion and acceptance of new computer construction projects in the smart services segment. Huachang Chemical expects net profit attributable to the parent company to be approximately 123 million yuan, up 1,025.93% year-on-year, benefiting from higher product sales prices and the commissioning of a polyol project. Guide Infrared expects net profit to be between 1.27 billion and 1.45 billion yuan, a year-on-year increase of 601.93% to 701.41%, driven by continued delivery of model project products and growth in the civilian infrared chip business. Tianfeng Securities expects net profit attributable to the parent company to be between 164 million and 246 million yuan, up 429.03% to 693.55% year-on-year, with increases in brokerage commission income and proprietary investment gains. Tianjin Printronics expects net profit attributable to the parent company to be between 36 million and 52 million yuan, a year-on-year increase of 435.64% to 673.71%, with sufficient orders on hand and capacity release at Taihe Circuit Technology. Haisco Pharmaceutical expects net profit attributable to the parent company to be between 790 million and 870 million yuan, up 513.25% to 575.35% year-on-year, with rapid growth in innovative drug sales and receipt of upfront payments for product out-licensing. Yachuang Electronics expects net profit attributable to the parent company to be between 220 million and 270 million yuan, a year-on-year increase of 439% to 561.49%, as the automotive electronics business improves and benefits from strategic cooperation in storage and passive components. Baoding Technology expects net profit attributable to the parent company to be between 125 million and 145 million yuan, up 468.71% to 559.71% year-on-year, with subsidiary Jinbao Electronics turning around its copper clad laminate and copper foil business, and Hexi Gold Mine benefiting from high gold prices. Xinxiang Chemical Fiber expects net profit attributable to the parent company to be between 300 million and 400 million yuan, a year-on-year increase of 378.09% to 537.45%, with higher sales volumes and gross margins for biomass cellulose filament and spandex fibers. Maxvision Technology expects net profit attributable to the parent company to be between 105 million and 135 million yuan, up 336.02% to 460.59% year-on-year, as computing power-related business begins to recognize revenue and becomes a new growth driver. Cangzhou Dahua expects net profit attributable to the parent company to be around 101 million yuan, an increase of about 330.75% year-on-year, with a significant rise in TDI market prices and increased market share for specialty PC.

Several listed companies on the Shanghai and Shenzhen stock exchanges issued important announcements on the evening of July 8. Tianhao Energy plans to acquire 100% equity of Tianhao New Energy, with shares resuming trading on the 9th. Hunan Gold plans to issue shares to acquire Gold Tianyue and Central South Smelting at a valuation of 4.334 billion yuan. Huahong Grace's purchase of 97.4988% equity of Huali Microelectronics and the associated fundraising plan have received approval for registration. In terms of earnings forecasts, BOE Technology expects first-half net profit to grow 54% to 69% year-on-year, Maxvision Technology expects growth of 336.02% to 460.59%, Haisco Pharmaceutical expects growth of 513.25% to 575.35%, and Huachang Chemical expects growth of 1025.93%. Additionally, Jingang Photovoltaic's controlling shareholder plans to increase its stake in the company by no less than 100 million yuan, and China Nerin Engineering signed an overseas project design and supply framework agreement contract worth approximately 1.123 billion yuan.

The IgA nephropathy clinical trial space is intensifying, with more than 25 companies actively developing over 30 pipeline drugs, according to a new report from DelveInsight. Key players include Haisco Pharmaceutical Group, Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca, Roche, Ionis Pharmaceuticals, Takeda, Arrowhead Pharmaceuticals, and others. Promising therapies in various trial phases include HSK39297, Zigakibart, Povetacicept, Felzartamab, Atacicept, ULTOMIRIS, Sefaxersen, TAK-079, ARO-C3, NM8074, WAL0921, KP104, PS-002, BHV-1400, CM313, NTQ5082, RNK288, and IFX 301. Approximately 12 or more drugs are in late-stage development, targeting mechanisms such as Complement Factor B inhibition, BAFF and APRIL antagonism, antibody-dependent cell cytotoxicity, Gd-IgA1 degradation, RNA interference, and CD38 antagonism. Recent milestones include positive Phase III data for Povetacicept and Atacicept, and publication of telitacicept results in the New England Journal of Medicine.

Haisco Pharmaceutical Group has signed an exclusive licensing agreement granting US-based Nuvectis worldwide rights outside specified Asian territories to develop, manufacture and commercialise drug candidates HSK42360 and HSK39297. Haisco will receive $40 million in upfront and near-term payments, with potential additional milestone payments totalling as much as $1.4 billion, plus tiered royalties on net sales. The first four milestone payments may be made in a mix of cash and common stock, with the equity component capped at under 40% of the milestone value. HSK42360 is a BRAF paradoxical breaker inhibitor in a Phase I trial in China, while HSK39297 is a complement factor B inhibitor with two new drug applications submitted in China for paroxysmal nocturnal haemoglobinuria. The agreement is subject to financing conditions to ensure Nuvectis can support development activities.